Cytokinetics (NASDAQ:CYTK – Get Score) was downgraded by equities analysis analysts at StockNews.com from a “maintain” ranking to a “promote” ranking in a report launched on Friday.
Different equities analysts additionally not too long ago issued analysis reviews in regards to the inventory. Mizuho initiated protection on shares of Cytokinetics in a analysis observe on Friday, September 2nd. They issued a “purchase” ranking and a $80.00 value goal for the corporate. Cantor Fitzgerald raised their value goal on Cytokinetics from $56.00 to $69.00 in a analysis observe on Monday, August fifteenth. Morgan Stanley lifted their value goal on Cytokinetics from $11.00 to $15.00 in a analysis report on Friday, August twelfth. Raymond James elevated their value goal on Cytokinetics from $54.00 to $63.00 in a report on Friday, August fifth. Lastly, UBS Group assumed protection on shares of Cytokinetics in a report on Tuesday, October eleventh. They issued a “purchase” ranking and a $80.00 goal value on the inventory. One analyst has rated the inventory with a promote ranking and 9 have given a purchase ranking to the inventory. In line with information from MarketBeat.com, Cytokinetics presently has a mean ranking of “Average Purchase” and a consensus goal value of $63.83.
Cytokinetics Inventory Down 5.0 %
Cytokinetics inventory traded down $2.00 throughout mid-day buying and selling on Friday, hitting $37.75. The corporate had a buying and selling quantity of 1,834,571 shares, in comparison with its common quantity of 1,171,212. The corporate has a fast ratio of 9.01, a present ratio of 9.01 and a debt-to-equity ratio of 1.77. Cytokinetics has a 1 12 months low of $29.26 and a 1 12 months excessive of $55.80. The enterprise has a fifty day shifting common of $49.28 and a 200 day shifting common of $44.85. The inventory has a market cap of $3.55 billion, a price-to-earnings ratio of -14.58 and a beta of 0.98.
Cytokinetics (NASDAQ:CYTK – Get Score) final issued its earnings outcomes on Thursday, August 4th. The biopharmaceutical firm reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.81. Cytokinetics had a adverse internet margin of 142.85% and a adverse return on fairness of 118.37%. The enterprise had income of $88.97 million throughout the quarter, in comparison with analysts’ expectations of $3.73 million. Throughout the identical quarter within the prior 12 months, the enterprise posted ($0.86) EPS. The corporate’s income for the quarter was up 3029.4% on a year-over-year foundation. On common, sell-side analysts anticipate that Cytokinetics will publish -3.71 earnings per share for the present fiscal 12 months.
Insider Shopping for and Promoting
In associated information, CEO Robert I. Blum offered 10,000 shares of the agency’s inventory in a transaction dated Wednesday, November 2nd. The shares have been offered at a mean value of $42.17, for a complete worth of $421,700.00. Following the completion of the sale, the chief government officer now owns 406,089 shares within the firm, valued at $17,124,773.13. The sale was disclosed in a authorized submitting with the SEC, which is obtainable via the SEC web site. In associated information, EVP Fady Ibraham Malik offered 21,500 shares of the corporate’s inventory in a transaction on Thursday, September eighth. The inventory was offered at a mean value of $51.88, for a complete transaction of $1,115,420.00. Following the transaction, the chief vp now owns 168,346 shares of the corporate’s inventory, valued at $8,733,790.48. The sale was disclosed in a submitting with the Securities & Alternate Fee, which is obtainable at this hyperlink. Additionally, CEO Robert I. Blum offered 10,000 shares of the inventory in a transaction on Wednesday, November 2nd. The inventory was offered at a mean value of $42.17, for a complete worth of $421,700.00. Following the completion of the transaction, the chief government officer now owns 406,089 shares of the corporate’s inventory, valued at roughly $17,124,773.13. The disclosure for this sale will be discovered right here. Insiders offered 124,772 shares of firm inventory valued at $6,238,694 over the past ninety days. Company insiders personal 5.00% of the corporate’s inventory.
Hedge Funds Weigh In On Cytokinetics
Numerous institutional buyers and hedge funds have not too long ago made adjustments to their positions within the inventory. CWM LLC boosted its holdings in Cytokinetics by 83.6% throughout the third quarter. CWM LLC now owns 538 shares of the biopharmaceutical firm’s inventory value $26,000 after shopping for an extra 245 shares within the final quarter. PNC Monetary Companies Group Inc. grew its holdings in shares of Cytokinetics by 6.1% within the 1st quarter. PNC Monetary Companies Group Inc. now owns 6,454 shares of the biopharmaceutical firm’s inventory value $236,000 after buying an extra 372 shares throughout the interval. State of Alaska Division of Income elevated its stake in Cytokinetics by 0.7% within the third quarter. State of Alaska Division of Income now owns 65,227 shares of the biopharmaceutical firm’s inventory valued at $3,160,000 after buying an extra 437 shares within the final quarter. Financial institution of Montreal Can raised its holdings in Cytokinetics by 1.9% throughout the first quarter. Financial institution of Montreal Can now owns 24,711 shares of the biopharmaceutical firm’s inventory value $940,000 after buying an extra 456 shares over the past quarter. Lastly, Dana Funding Advisors Inc. boosted its place in Cytokinetics by 2.9% throughout the first quarter. Dana Funding Advisors Inc. now owns 17,351 shares of the biopharmaceutical firm’s inventory value $639,000 after buying an extra 489 shares within the final quarter.
About Cytokinetics
(Get Score)
Cytokinetics, Integrated, a late-stage biopharmaceutical firm, focuses on discovering, growing, and commercializing muscle activators and inhibitors as potential therapies for debilitating illnesses. The corporate develops small molecule drug candidates primarily engineered to impression muscle operate and contractility.
Featured Tales
This instantaneous information alert was generated by narrative science expertise and monetary information from MarketBeat with a purpose to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you take into account Cytokinetics, you will need to hear this.
MarketBeat retains monitor of Wall Avenue’s top-rated and greatest performing analysis analysts and the shares they advocate to their purchasers each day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Cytokinetics wasn’t on the listing.
Whereas Cytokinetics at present has a “Purchase” ranking amongst analysts, top-rated analysts imagine these 5 shares are higher buys.
View The 5 Shares Right here
